33 results on '"Goll, Guro L"'
Search Results
2. Generic Tofacitinib—A More Affordable JAK Inhibitor
3. Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases
4. Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
5. Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway
6. Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases.
7. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
8. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
9. Biosimilar tocilizumab—better access and lower cost?
10. Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study
11. Immunogenicity and Safety of Standard and Third‐Dose SARS – CoV ‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
12. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases
13. Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY
14. 231: PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; RESULTS FROM A 52-WEEK MULTICENTRE RANDOMISED TRIAL OF 450 PATIENTS
15. 101: GENETIC PREDISPOSITION TO INFLIXIMAB IMMUNOGENICITY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES – SECONDARY ANALYZES FROM A RANDOMIZED TRIAL
16. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.
17. What Next after Biologic Therapy Fails in Rheumatoid Arthritis?
18. An Opportunity Missed: Biosimilars in the United States
19. The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis
20. Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs
21. Confiance des rhumatologues quant au passage à un biosimilaire
22. Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
23. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
24. The confidence of rheumatologists about switching to biosimilars for their patients
25. New-generation JAK inhibitors: how selective can they be?
26. 815 - Long-Term Efficacy and Safety of CT-P13 after Switching from Originator Infliximab: Exploratory Subgroup Analyses in IBD in the Nor-Switch Extension Trial
27. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
28. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
29. Biosimilar Infliximab (CT-P13) is not Inferior to Originator Infliximab: Explorative IBD Subgroup-Analyses in Crohn's Disease and Ulcerative Colitis from the Nor-Switch Trial
30. 249 - Biosimilar Infliximab (CT-P13) is not Inferior to Originator Infliximab: Explorative IBD Subgroup-Analyses in Crohn's Disease and Ulcerative Colitis from the Nor-Switch Trial
31. Cartilage and Bone Biomarkers in Rheumatoid Arthritis: Prediction of 10-year Radiographic Progression
32. A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients
33. Generic Tofacitinib—A More Affordable JAK Inhibitor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.